Saturday - August 2, 2025
EU Approves SARCLISA for Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma
July 26, 2025
NORTH HOLLYWOOD, California, July 26 -- The International Myeloma Foundation issued the following news:

* * *

EU Approves SARCLISA(R) (isatuximab-irfc) for the Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma

On Friday, July 25, the European Union (EU) approved Sarclisa (isatuximab-irfc) to be used "in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for the induction treatment of adult patients with newly diagnosed m . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products